2. Cell Cycle/DNA Damage Anti-infection Metabolic Enzyme/Protease
  3. DNA/RNA Synthesis Bacterial Antibiotic Glutathione S-transferase
  4. Plicamycin

Plicamycin  (Synonyms: Mithramycin A)

Cat. No.: HY-A0122 Purity: 99.75%
SDS COA Handling Instructions

Molarity Calculator

Plicamycin (Mithramycin A) is a selective specificity protein 1 (Sp1) inhibitor. Plicamycin inhibits the growth of various cancers by decreasing Sp1 protein. Plicamycin inhibits GSTM2 promoter activity and protein expression.

For research use only. We do not sell to patients.

Plicamycin Chemical Structure

Plicamycin Chemical Structure

CAS No. : 18378-89-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 572 In-stock
Solution
10 mM * 1 mL in DMSO USD 572 In-stock
Solid
1 mg USD 170 In-stock
5 mg USD 520 In-stock
10 mg USD 830 In-stock
25 mg USD 1780 In-stock
50 mg USD 2850 In-stock
100 mg USD 4550 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 32 publication(s) in Google Scholar

Plicamycin Related Antibodies

Top Publications Citing Use of Products

    Plicamycin purchased from MedChemExpress. Usage Cited in: Immunol Invest. 2022 Dec 23;1-17.  [Abstract]

    Plicamycin (0, 50, 100, 200, 500 nM; 24 h) reduces IL-34 expression.

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Plicamycin (Mithramycin A) is a selective specificity protein 1 (Sp1) inhibitor. Plicamycin inhibits the growth of various cancers by decreasing Sp1 protein. Plicamycin inhibits GSTM2 promoter activity and protein expression[1][2].

    IC50 & Target

    GSTM2

     

    Cellular Effect
    Cell Line Type Value Description References
    A549 GI50
    71 nM
    Compound: 1; MTM
    Growth inhibition of human A549 cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human A549 cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    A673 GI50
    46 nM
    Compound: 1; MTM
    Growth inhibition of human A673 cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human A673 cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    DMS-114 GI50
    71 nM
    Compound: 1; MTM
    Growth inhibition of human DMS114 cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human DMS114 cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    DU-145 GI50
    71 nM
    Compound: 1; MTM
    Growth inhibition of human DU145 cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human DU145 cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    ES7 GI50
    46 nM
    Compound: 1; MTM
    Growth inhibition of human ES7 cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human ES7 cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    ES8 GI50
    46 nM
    Compound: 1; MTM
    Growth inhibition of human ES8 cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human ES8 cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    HCT-116 GI50
    71 nM
    Compound: 1; MTM
    Growth inhibition of human HCT116 cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human HCT116 cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    HeLa GI50
    71 nM
    Compound: 1; MTM
    Growth inhibition of human HeLa cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human HeLa cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    LNCaP GI50
    71 nM
    Compound: 1; MTM
    Growth inhibition of human LNCAP cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human LNCAP cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    PANC-1 GI50
    71 nM
    Compound: 1; MTM
    Growth inhibition of human PANC1 cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human PANC1 cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    PC-3 GI50
    83 nM
    Compound: 1; MTM
    Growth inhibition of human PC3 cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human PC3 cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    Prostatic carcinoma cell GI50
    48 nM
    Compound: 1; MTM
    Growth inhibition of human prostate cancer cell cells lacking TMPRSS2-ERG gene incubated for 72 hrs by resazurin based assay
    Growth inhibition of human prostate cancer cell cells lacking TMPRSS2-ERG gene incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    TC-32 GI50
    32 nM
    Compound: 1; MTM
    Growth inhibition of human TC32 cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human TC32 cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    U-118-MG GI50
    71 nM
    Compound: 1; MTM
    Growth inhibition of human U118MG cells incubated for 72 hrs by resazurin based assay
    Growth inhibition of human U118MG cells incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    VCaP GI50
    41 nM
    Compound: 1; MTM
    Growth inhibition of human VCaP cells overexpressing TMPRSS2-ERG gene incubated for 72 hrs by resazurin based assay
    Growth inhibition of human VCaP cells overexpressing TMPRSS2-ERG gene incubated for 72 hrs by resazurin based assay
    		[PMID: 30114371]
    In Vitro

    Plicamycin (Mith) decreases Sp1 protein by inducing proteasome-dependent degradation, thereby suppressing cervical cancer growth through a DR5/caspase-8/Bid signaling pathway. Plicamycin inhibits HEp-2 and KB cell growth in a concentration-dependent manner after 48 h. Apoptotic cell death is qualitatively estimated by DAPI staining for nuclear condensation and fragmentation. Plicamycin leads to significant DNA fragmentation compared to untreated controls[1].
    Plicamycin (mithramycin A) (0-400 nM, 24 h) dose-dependently inhibited GSTM2 protein expression in BFTC 905 and 5637 cells; SP1 overexpression increased GSTM2 protein expression in BFTC 905 and 5637 cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Plicamycin Related Antibodies
    In Vivo

    The antitumorigenic activity of Plicamycin (0.2 mg/kg/day) is determined in a xenograft model and observed reduction in tumor volume and weight. No significant mouse body weight loss is observed in Plicamycin-treatment groups, indicating that Plicamycin-associated toxicity is minimal. Plicamycin also increases TUNEL-positive cells in tumor xenografts. No notable intergroup differences are observed among organs, indicating no marked signs of systemic toxicity at the Plicamycin dose used in this study[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Molecular Weight

    1085.15

    Formula

    C52H76O24
    CAS No.
    Appearance

    Solid

    Color

    Yellow to brown

    SMILES

    O=C([C@H]([C@@]([C@H](OC)C([C@@H](O)[C@H](O)C)=O)([H])C1)O[C@@](O[C@H](C)[C@H]2O)([H])C[C@H]2O[C@@](O[C@H](C)[C@@H]3O)([H])C[C@H]3O[C@@](O[C@H](C)[C@H]4O)([H])C[C@@]4(O)C)C(C1=CC5=CC(O[C@H](O[C@H](C)[C@H]6O)C[C@H]6O[C@@](O[C@H](C)[C@H]7O)([H])C[C@H]7O)=C(C)C(O)=C85)=C8O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (92.15 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 0.9215 mL 4.6077 mL 9.2153 mL
    5 mM 0.1843 mL 0.9215 mL 1.8431 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (2.30 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (2.30 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.75%

    SDS (393 KB)

    COA (259 KB) HNMR (323 KB) RP-HPLC (262 KB) LCMS (104 KB)

    Handling Instructions (2659 KB)
    References
    Cell Assay
    [1]

    HEp-2 cells and KB cells are cultured in DMEM 100 U/mL each of Penicillin and Streptomycin and 10% FBS for HEp-2 cells and 5% FBS for KB in a humidified atmosphere containing 5% CO2 at 37°C. Equal numbers of cells are seeded and allowed to attach. At 50-60% confluence, cells are treated with DMSO or indicated concentrations of Plicamycin (50, 100, and 200 nM for HEp-2 cells; 20, 40, and 80 nM for KB cells). Cell viability is determined using CellTiter 96 Aqueous One Solution Cell Proliferation Assay Kits. In brief, cells are seeded in 96-well plates and incubated with Plicamycin. After treatment, 30 µL MTS solution is added to each well and cells are incubated for 2 h at 37°C. MTS solution is analyzed using a microplate reader at 490 nm and 690 nm[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    Mice[1]
    Female nude mice are used. KB cells are suspended in sterile PBS and injected subcutaneously into the right flank of mice. Mice are randomized into two groups containing five mice each and treated with 0.2 mg/kg/day of Plicamycin (i.p.) three times per week for 29 days. Control mice receive an equal volume of vehicle. After 29 days, bodies, organs and tumors are weighed and tumor volumes determined. Tumors are measured[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 0.9215 mL 4.6077 mL 9.2153 mL 23.0383 mL
    5 mM 0.1843 mL 0.9215 mL 1.8431 mL 4.6077 mL
    10 mM 0.0922 mL 0.4608 mL 0.9215 mL 2.3038 mL
    15 mM 0.0614 mL 0.3072 mL 0.6144 mL 1.5359 mL
    20 mM 0.0461 mL 0.2304 mL 0.4608 mL 1.1519 mL
    25 mM 0.0369 mL 0.1843 mL 0.3686 mL 0.9215 mL
    30 mM 0.0307 mL 0.1536 mL 0.3072 mL 0.7679 mL
    40 mM 0.0230 mL 0.1152 mL 0.2304 mL 0.5760 mL
    50 mM 0.0184 mL 0.0922 mL 0.1843 mL 0.4608 mL
    60 mM 0.0154 mL 0.0768 mL 0.1536 mL 0.3840 mL
    80 mM 0.0115 mL 0.0576 mL 0.1152 mL 0.2880 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Plicamycin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Plicamycin18378-89-7Mithramycin ADNA/RNA SynthesisBacterialAntibioticGlutathione S-transferaseGlutathione transferasesGSTsInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Plicamycin
    Cat. No.:
    HY-A0122
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.